Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man.
1. Preliminary studies in man of a new beta-adrenoceptive receptor blocking drug, DL-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), are described.2. LB46, 0.5 mg by oral administration, appeared to be of similar potency to propranolol 20 mg in inhibiting isoprenaline-induced and exercise-induced tachycardia.3. In comparable beta-receptor blocking doses LB46 did not show the negative chronotropic property possessed by propranolol.
D000328:Adult; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D008297:Male; D005082:Physical Exertion; D010919:Placebos; D011955:Receptors, Drug; D013565:Sympatholytics / Q000008:administration & dosage / Q000494:pharmacology*
D010919:Placebos; D011955:Receptors, Drug; D013565:Sympatholytics; D007545:Isoproterenol